Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.

Hdl Handle:
http://hdl.handle.net/10147/207491
Title:
Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
Authors:
Duffy, Michael J; van Rossum, Leo G M; van Turenhout, Sietze T; Malminiemi, Outi; Sturgeon, Catherine; Lamerz, Rolf; Nicolini, Andrea; Haglund, Caj; Holubec, Lubos; Fraser, Callum G; Halloran, Stephen P
Affiliation:
Department of Pathology and Laboratory Medicine, St Vincent's University, Hospital, Dublin and UCD School of Medicine and Medical Science, University, College Dublin, Dublin, Ireland. Michael.J.Duffy@ucd.ie
Citation:
Int J Cancer. 2011 Jan 1;128(1):3-11. doi: 10.1002/ijc.25654.
Journal:
International journal of cancer. Journal international du cancer
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207491
DOI:
10.1002/ijc.25654
PubMed ID:
20824704
Abstract:
Several randomized controlled trials have shown that population-based screening using faecal occult blood testing (FOBT) can reduce mortality from colorectal neoplasia. Based on this evidence, a number of countries have introduced screening for colorectal cancer (CRC) and high-risk adenoma and many others are considering its introduction. The aim of this article is to critically review the current status of faecal markers as population-based screening tests for these neoplasia. Most of the available faecal tests involve the measurement of either occult blood or a panel of DNA markers. Occult blood may be measured using either the guaiac faecal occult blood test (gFOBT) or a faecal immunochemical test (iFOBT). Although iFOBT may require a greater initial investment, they have several advantages over gFOBT, including greater analytical sensitivity and specificity. Their use results in improved clinical performance and higher uptake rates. Importantly for population screening, some of the iFOBTs can be automated and provide an adjustable cutoff for faecal haemoglobin concentration. However, samples for iFOBT, may be less stable after collection than for gFOBT. For new centres undertaking FOBT for colorectal neoplasia, the European Group on Tumour Markers recommends use of a quantitative iFOBT with an adjustable cutoff point and high throughput analysis. All participants with positive FOBT results should be offered colonoscopy. The panel recommends further research into increasing the stability of iFOBT and the development of improved and affordable DNA and proteomic-based tests, which reduce current false negative rates, simplify sample transport and enable automated analysis.
Language:
eng
MeSH:
Colorectal Neoplasms/diagnosis/genetics/*metabolism; DNA, Neoplasm/analysis; Europe; Feces/*chemistry; Humans; Mass Screening/*methods; Occult Blood; Predictive Value of Tests; Reproducibility of Results; Tumor Markers, Biological/*analysis
ISSN:
1097-0215 (Electronic); 0020-7136 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorDuffy, Michael Jen_GB
dc.contributor.authorvan Rossum, Leo G Men_GB
dc.contributor.authorvan Turenhout, Sietze Ten_GB
dc.contributor.authorMalminiemi, Outien_GB
dc.contributor.authorSturgeon, Catherineen_GB
dc.contributor.authorLamerz, Rolfen_GB
dc.contributor.authorNicolini, Andreaen_GB
dc.contributor.authorHaglund, Cajen_GB
dc.contributor.authorHolubec, Lubosen_GB
dc.contributor.authorFraser, Callum Gen_GB
dc.contributor.authorHalloran, Stephen Pen_GB
dc.date.accessioned2012-02-01T10:29:20Z-
dc.date.available2012-02-01T10:29:20Z-
dc.date.issued2012-02-01T10:29:20Z-
dc.identifier.citationInt J Cancer. 2011 Jan 1;128(1):3-11. doi: 10.1002/ijc.25654.en_GB
dc.identifier.issn1097-0215 (Electronic)en_GB
dc.identifier.issn0020-7136 (Linking)en_GB
dc.identifier.pmid20824704en_GB
dc.identifier.doi10.1002/ijc.25654en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207491-
dc.description.abstractSeveral randomized controlled trials have shown that population-based screening using faecal occult blood testing (FOBT) can reduce mortality from colorectal neoplasia. Based on this evidence, a number of countries have introduced screening for colorectal cancer (CRC) and high-risk adenoma and many others are considering its introduction. The aim of this article is to critically review the current status of faecal markers as population-based screening tests for these neoplasia. Most of the available faecal tests involve the measurement of either occult blood or a panel of DNA markers. Occult blood may be measured using either the guaiac faecal occult blood test (gFOBT) or a faecal immunochemical test (iFOBT). Although iFOBT may require a greater initial investment, they have several advantages over gFOBT, including greater analytical sensitivity and specificity. Their use results in improved clinical performance and higher uptake rates. Importantly for population screening, some of the iFOBTs can be automated and provide an adjustable cutoff for faecal haemoglobin concentration. However, samples for iFOBT, may be less stable after collection than for gFOBT. For new centres undertaking FOBT for colorectal neoplasia, the European Group on Tumour Markers recommends use of a quantitative iFOBT with an adjustable cutoff point and high throughput analysis. All participants with positive FOBT results should be offered colonoscopy. The panel recommends further research into increasing the stability of iFOBT and the development of improved and affordable DNA and proteomic-based tests, which reduce current false negative rates, simplify sample transport and enable automated analysis.en_GB
dc.language.isoengen_GB
dc.subject.meshColorectal Neoplasms/diagnosis/genetics/*metabolismen_GB
dc.subject.meshDNA, Neoplasm/analysisen_GB
dc.subject.meshEuropeen_GB
dc.subject.meshFeces/*chemistryen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMass Screening/*methodsen_GB
dc.subject.meshOccult Blooden_GB
dc.subject.meshPredictive Value of Testsen_GB
dc.subject.meshReproducibility of Resultsen_GB
dc.subject.meshTumor Markers, Biological/*analysisen_GB
dc.titleUse of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.en_GB
dc.contributor.departmentDepartment of Pathology and Laboratory Medicine, St Vincent's University, Hospital, Dublin and UCD School of Medicine and Medical Science, University, College Dublin, Dublin, Ireland. Michael.J.Duffy@ucd.ieen_GB
dc.identifier.journalInternational journal of cancer. Journal international du canceren_GB
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.